DAWN Day One Biopharmaceuticals, Inc.

8-K Current Report

Filed: March 2, 2026

Health Care

Pharmaceutical Preparations

Day One Biopharmaceuticals, Inc. Overview

Day One Biopharmaceuticals, Inc. (DAWN) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• EU positive opinion received for OJEMDA (tovorafenib) in pediatric low-grade glioma — key step toward conditional marketing authorization in Europe
• Target indication: relapsed/refractory BRAF-altered pediatric low-grade glioma, same label as US approval

+2 more insights

Other Day One Biopharmaceuticals, Inc. 8-K Filings

8-K Mar 6, 2026

8-K Feb 24, 2026

Get deeper insights on Day One Biopharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.